Sclerostin levels and bone turnover markers in adolescents with anorexia nervosa and healthy adolescent girls.
Sclerostin, product of the SOST gene, is an important determinant of bone formation and resorption. Adolescents with anorexia nervosa (AN) have low bone density and decreased levels of bone turnover markers. However, sclerostin has not been examined in AN as a potential mediator of impaired bone metabolism. Our study objectives were to (i) assess associations of sclerostin with surrogate bone turnover markers in girls with AN and controls and (ii) examine effects of transdermal estradiol on sclerostin in AN. 69 girls (44 with AN and 25 normal-weight controls) 13-18 years old were studied at baseline. 22 AN girls were randomized to transdermal estradiol (plus cyclic medroxyprogesterone) or placebo in a double-blind study for 12 months. Sclerostin correlated positively with P1NP and CTX in controls (r=0.67 and 0.53, p=0.0002 and 0.005, respectively) but not in AN despite comparable levels at baseline. Changes in sclerostin over twelve months did not differ in girls randomized to estradiol or placebo. The relationship between sclerostin and bone turnover markers is disrupted in adolescent girls with AN. Despite an increase in BMD with estradiol administration in AN, estrogen does not impact sclerostin levels in this group.
Neuroendocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Alexander T
AT
Faje
Pouneh K
PK
Fazeli
Debra K
DK
Katzman
Karen K
KK
Miller
Anne
A
Breggia
Clifford J
CJ
Rosen
Nara
N
Mendes
Anne
A
Klibanski
Madhusmita
M
Misra
D048868:Adaptor Proteins, Signal Transducing; D000293:Adolescent; D000856:Anorexia Nervosa / Q000097:blood* / Q000188:drug therapy / Q000503:physiopathology*; D015415:Biomarkers / Q000097:blood; D001823:Body Composition / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D015519:Bone Density / Q000187:drug effects; D019485:Bone Morphogenetic Proteins / Q000097:blood*; D016723:Bone Remodeling / Q000187:drug effects; D016022:Case-Control Studies; D004958:Estradiol / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D005819:Genetic Markers; D006262:Health; D020249:Hormone Replacement Therapy; D006801:Humans
D048868:Adaptor Proteins, Signal Transducing; D015415:Biomarkers; D019485:Bone Morphogenetic Proteins; D005819:Genetic Markers; C422903:SOST protein, human; D004958:Estradiol